Spots Global Cancer Trial Database for cholangiocarcinoma, extrahepatic
Every month we try and update this database with for cholangiocarcinoma, extrahepatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors | NCT04400357 | Pancreatic Aden... Pancreatic Cyst... Pancreatic Endo... Chronic Pancrea... Cholangiocarcin... Ampullary Adeno... Duodenal Adenoc... | Robotic pancrea... Open pancreatic... | 18 Years - | Ruijin Hospital | |
| Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors | NCT04400357 | Pancreatic Aden... Pancreatic Cyst... Pancreatic Endo... Chronic Pancrea... Cholangiocarcin... Ampullary Adeno... Duodenal Adenoc... | Robotic pancrea... Open pancreatic... | 18 Years - | Ruijin Hospital | |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) | NCT03414489 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... | ABC294640 | 18 Years - | RedHill Biopharma Limited | |
| Recurrence After Whipple's (RAW) Study | NCT04596865 | Pancreatic Canc... Ampullary Cance... Bile Duct Cance... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Pancreatic Duct... Pancreatic Duct... Surgery Survivorship Recurrent Cance... Cancer Recurren... Cancer Recurren... Local Recurrenc... | Pancreaticoduod... | - | University Hospital Plymouth NHS Trust | |
| Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) | NCT03414489 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... | ABC294640 | 18 Years - | RedHill Biopharma Limited |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
